Background/Objectives: Immune checkpoint inhibitor (ICI)-associated cardiovascular adverse events are relatively uncommon; they can be life-threatening, particularly when involving malignant ventricular arrhythmias. Electrocardiographic markers such as P-wave dispersion (PWD), QT dispersion (QTd), T-peak to T-end (Tp-e) interval, and Tp-e/QT and Tp-e/QTc ratios have been linked to an elevated risk of both atrial and ventricular arrhythmias and sudden cardiac death across various cardiac conditions. Monitoring these parameters may aid in identifying the risk of arrhythmogenic events in cancer patients undergoing ICI therapy. Methods: This retrospective cohort study analyzed 42 patients with cancer who received ICI therapy and had serial 12-lead electrocardiograms (ECGs) performed at baseline and at three-month intervals during the first year of treatment, from May 2022 to November 2023. ECG parameters including PWD, QTd, Tp-e interval, and Tp-e/QT and Tp-e/QTc ratios were measured and compared between baseline and follow-up time points. Results: The median follow-up duration was 5.3 months (range: 0.5–18.9 months). No statistically significant differences were observed in any of the ECG parameters between baseline and subsequent measurements (p > 0.05). One patient developed atrial fibrillation during the third month of treatment. Additionally, one patient exhibited a left anterior fascicular block, and another experienced frequent ventricular extrasystoles. No malignant ventricular arrhythmias were reported throughout the study period. Conclusions: This study found no significant changes in electrocardiographic markers associated with arrhythmia risk during ICI treatment. Larger, multicenter, prospective studies with extended follow-up are warranted to further elucidate the cardiovascular safety profile of ICIs.

The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.

Contrast-associated acute kidney injury (CA-AKI) is an important complication of renal angiography in patients with atherosclerotic renal artery stenosis (RAS). We investigated the associations of the triglyceride–glucose (TyG) index, atherogenic coefficient (AC) and lipoprotein combined index (LCI) with CA-AKI in this population. This retrospective single-center study included 147 consecutive patients with atherosclerotic RAS undergoing renal angiography with or without renal artery intervention. CA-AKI was defined using a creatinine-based definition based on serum creatinine changes within 48–72 h after contrast exposure. Continuous variables were retained in their continuous form in the primary logistic regression analyses, and separate multivariable models were constructed for the TyG index, AC, and LCI, each adjusted for chronic kidney disease (CKD), left ventricular ejection fraction (LVEF), and contrast volume. Firth penalized logistic regression was performed as a sensitivity analysis. CA-AKI occurred in 22 patients (15.0%). In the adjusted model, a higher TyG index was associated with increased odds of CA-AKI (OR 4.263 per 1-unit increase, 95% CI 1.120–16.228; p = 0.034), whereas AC (OR 1.581, 95% CI 0.891–2.807; p = 0.118) and LCI (OR 1.047 per 10,000-unit increase, 95% CI 0.966–1.136; p = 0.264) were not significantly associated with CA-AKI. The association of the TyG index with CA-AKI remained significant in Firth penalized logistic regression (OR 3.48, 95% CI 1.17–14.33; p = 0.020). Higher contrast volume and lower LVEF were consistently associated with CA-AKI across the multivariable models. These findings suggest that the TyG index is associated with susceptibility to CA-AKI in patients with atherosclerotic RAS, although prospective validation is required before clinical application.

Aim: Transcatheter aortic valve implantation (TAVI) has become a well-recognized treatment option for patients with symptomatic severe aortic stenosis (AS) who are deemed to have a higher risk for surgical intervention. Due to underlying comorbidities, acute kidney injury (AKI) continues to be a common complication, especially in patients with diabetes mellitus after TAVR. The aim of this study is to evaluate the effect of postoperative AKI development in diabetic patients undergoing TAVR on the development of mortality and major adverse cardiac events (MACE) in these patients. Material and Method: A total of 141 patients who underwent TAVR between January 2015 and January 2020 were grouped according to whether they developed AKI and whether they had MACE. MACE and 5-year mortality status were compared according to whether the patients developed AKI. Results: A total of 35 patients were observed to develop AKI (24.8%). Additionally, MACE was observed in 36 patients (25.5%). Five-year mortality rates (42.9% vs. 15.1%; p = 0.002) and MACE rates (54.3% vs. 16%; p < 0.001) were significantly higher in the AKI group. Univariate and multivariate logistic regression analyses identified AKI as a significant independent predictor of MACE development, regardless of other associated parameters (OR = 3.92, 95% CI: 1.28–12.02; p = 0.017). Conclusion: The most important result obtained in this study is that AKI development in diabetic patients who underwent TAVR with the diagnosis of advanced aortic stenosis has an effect on the development of MACE and long-term mortality independently of other parameters.